Janssen study shows benefits of Invokana for diabetes and chronic kidney disease

Janssen has announced the findings of a clinical study showing the benefits its drug Invokana can deliver for people with type 2 diabetes and chronic kidney disease.

An additional analysis from the landmark CANVAS programme has shown that Invokana improved renal outcomes in people with type 2 diabetes with or at high risk for cardiovascular disease.

This benefit was observed in people with preserved and reduced kidney function, with the drug reducing the urinary albumin to creatinine ratio – a key biomarker for chronic kidney disease.

Following the positive conclusion of this analysis, the company will assess the further benefits of Invokana in a study called CREDENCE, which represents the first dedicated SGLT2 inhibitor trial evaluating renal and cardiovascular outcomes in people with type 2 diabetes and kidney disease.

Dr James List, global therapeutic area head for cardiovascular and metabolism at Janssen Research and Development, said: "We are encouraged that canagliflozin could potentially provide much-needed benefit for those with diabetic kidney disease, and look forward to building further on this insight in CREDENCE."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.